CHA, Sorrento JV Highlights Korean Immuno-Oncology Appetite
Sorrento and CHA Biotech’s agreement to form a CAR-NK cell therapy joint venture is very much “on trend”, being the latest in a recent series of immuno-oncology collaborations between Korean and foreign firms and indicating a rapidly growing appetite for assets in the field.
You may also be interested in...
Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.
Two South Korean stem cell therapy ventures, Corestem and CHA Biotech, are taking divergent strategies in R&D and commercialization, one pushing ahead with the rapid launch of its first product and the other taking time to optimize its pipeline. During a recent stem cell industry investor relations session in Seoul, the companies unveiled the thinking behind their pipeline progress and business strategies.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.